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Abstract
Anticoagulation is central to the management of thrombotic antiphospholipid syn-
drome (APS). The standard anticoagulant treatment for thrombotic APS is life- long 
warfarin or an alternative vitamin K antagonist. The role of direct oral anticoagulants 
for thrombotic APS is not established due to the lack of definitive evidence and has 
recently been addressed in international guidance. Other anticoagulant options in-
clude low molecular weight heparin, unfractionated heparin, and fondaparinux. In 
APS patients, lupus anticoagulant can affect phospholipid- dependent coagulation 
monitoring tests, so that they may not reflect true anticoagulation intensity. Accurate 
assessment of anticoagulation intensity is essential, to optimize anticoagulant dosing 
and facilitate thrombus resolution; minimize the risk of recurrent thrombosis or bleed-
ing; inform assessment of whether recurrent thrombosis is related to breakthrough 
thrombosis while on therapeutic anticoagulation, subtherapeutic anticoagulation, non- 
adherence, or spurious results; and guide the management of bleeding. Knowledge of 
anticoagulant intensity also informs assessment and comparison of anticoagulation 
regimens in clinical studies. Considerations regarding anticoagulation dosing and/or 
monitoring of thrombotic APS patients underpin appropriate management in special 
situations, notably APS- related severe renal impairment, which can occur in APS or 
APS/systemic lupus erythematosus- related nephropathy or catastrophic APS; and 
APS- related thrombocytopenia. Anticoagulant dosing and monitoring in thrombotic 
APS patients also require consideration in anticoagulant- refractory APS and during 
pregnancy. In this review, we summarize the tests generally used in monitoring an-
ticoagulant therapy, use of the main anticoagulants considered for thrombotic APS, 
lupus anticoagulant effects on anticoagulation monitoring tests, and strategies for 
appropriate anticoagulant monitoring in thrombotic APS.
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1  |  INTRODUC TION
Antiphospholipid syndrome (APS) is an acquired autoimmune 
disorder characterized by thrombosis and/or pregnancy mor-
bidity in association with persistent antiphospholipid antibodies 
(aPL; lupus anticoagulant [LA], anticardiolipin [aCL], and/or anti- 
beta- 2- glycoprotein I [aβ2GPI]).
1,2 Thrombosis may be venous, 
arterial, and/or microvascular.1 Catastrophic APS (CAPS), the 
most severe form of APS, which occurs in approximately 1% of 
APS patients and has a mortality rate of ~ 30%, is associated 
with mainly multiple small vessel thromboses leading to a dis-
seminated microangiopathic syndrome.3,4 In a prospective study, 
thrombotic APS, noted in ~ 15% of patients with systemic lupus 
erythematosus (SLE), was a major predictor of irreversible organ 
damage and death.5
The main thrombotic manifestations of APS are lower limb 
deep venous thromboses (DVT) and pulmonary emboli, or 
strokes and transient ischemic attacks (TIAs), accounting for ap-
proximately 50% and 30%, respectively.6 A systematic review 
estimated that 10% of patients with DVT have aPL,7 with the 
prevalence of thrombotic APS in individuals with a first unpro-
voked venous thromboembolism (VTE) episode 9%, both in a pro-
spective study in 290 patients8 and a cross- sectional study in 491 
patients < 50 years.9 Systematic reviews suggest that ~ 14% of 
patients with ischemic strokes and 17% of those under the age 
of 50 years have aPL.7,10 These figures, as well as the estimated 
prevalence of APS, 50 per 100 000 of the population, with ap-
proximately 80% of patients having DVT or pulmonary embo-
lism, and 45% stroke or TIA,11 suggest possible underdiagnosis 
of thrombotic APS.
Anticoagulation is central to the management of thrombotic 
APS. The standard anticoagulant treatment for thrombotic 
APS is life- long warfarin or an alternative vitamin K antagonist 
(VKA). The role of direct oral anticoagulants (DOACs) for throm-
botic APS has not been established due to the lack of defini-
tive evidence, and has been addressed in International Society 
on Thrombosis and Haemostasis (ISTH) and 16th International 
Congress on Antiphospholipid Antibodies Task Force Report on 
APS Treatment Trends guidance.12,13 Parenteral anticoagulant 
options in APS include low molecular weight heparin (LMWH), 
unfractionated heparin (UFH), and fondaparinux. LMWH, in 
combination with low dose aspirin (LDA), is standard treatment 
for thrombotic APS during pregnancy.14 Figure 1 summarizes 
coagulation mechanisms and targets for actions of different 
anticoagulants.15 Anticoagulation, in combination with corti-
costeroids, plasma exchange, and/or intravenous immunoglob-
ulin (IVIG), is standard treatment for CAPS.3,4,16 Non- criteria 
APS manifestations, which include livedo reticularis, thrombo-
cytopenia, hemolytic anemia, cardiac valve disease, nephrop-
athy, skin ulcers, and cognitive dysfunction,1 are generally 
anticoagulant- refractory and require consideration of further 
therapeutic approaches.
2  |  WHAT IS PARTICUL AR ABOUT 
ANTICOAGUL ATION MONITORING IN 
THROMBOTIC APS?
Accurate assessment of anticoagulation intensity is essential, to 
optimize anticoagulant dosing and facilitate thrombus resolution; 
minimize the risk of recurrent thrombosis or bleeding; inform assess-
ment of whether recurrent thrombosis is related to breakthrough 
thrombosis while on therapeutic anticoagulation, subtherapeutic 
anticoagulation, non- adherence, or spurious results; and guide the 
management of bleeding. Knowledge of anticoagulant intensity also 
informs assessment and comparison of anticoagulation regimens in 
clinical studies. Considerations regarding anticoagulant dosing and/
or monitoring of thrombotic APS patients underpin appropriate 
management in special situations, notably APS- related severe renal 
impairment, that can occur in APS or APS/SLE- related nephropathy 
or CAPS; and APS- related thrombocytopenia. Anticoagulant dosing 
and monitoring in thrombotic APS patients also require considera-
tion in anticoagulant- refractory APS patients and during pregnancy. 
Monitoring of anticoagulation may be hampered by the presence 
of aPL. In LA- positive APS patients, LA can affect phospholipid- 
dependent coagulation monitoring tests, so that they may not re-
flect true anticoagulation intensity.17- 19
As in non- APS patients, anticoagulation monitoring should be ac-
companied by ongoing assessment of venous and arterial thrombotic 
risk factors and their optimization, and proactive management of po-
tential bleeding risk factors. In addition, patients should be counselled 
about anticoagulation, with points addressed including the dose reg-
imen, what to do in the event of bleeding or symptoms suggestive of 
recurrent thrombosis, and potential interacting drugs. In this review, 
we summarize tests generally used in monitoring anticoagulant ther-
apy, use of the main anticoagulants considered for thrombotic APS, 
LA effects on anticoagulation monitoring tests, and strategies for ap-
propriate anticoagulant monitoring in thrombotic APS.
3  |  TESTS USED IN MONITORING 
ANTICOAGUL ANT THER APY
3.1  |  Prothrombin time- international normalized 
ratio (PT- INR)
The INR is derived from the PT screening coagulation test (sensitive to 
reduced activity of factors (F)I (fibrinogen), II (prothrombin), V, VII, and 
X, according to the formula: INR=(patient's PT/MNPT)ISI, where the 
MNPT is the mean normal PT and ISI is the international sensitivity 
index, a correction factor applied to adjust for differences in instru-
ment and reagent sensitivity. Accurate INR determination is critically 
dependent upon accurate definition of the MNPT and ISI for the rea-
gent/instrument combination. Guidance is available for appropriate ISI 
verification/validation, to help reduce inter- laboratory variability.20 A 
European Committee for External Quality Assurance Programmes in 
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Laboratory Medicine study demonstrated that between- laboratory 
INR variation was lower after local INR calibration (coefficient of vari-
ation [CV] 6.7% vs. 8.6), which is strongly recommended.21
3.2  |  Point- of- care PT- INR testing
Several point- of- care (POC) devices have been shown to give reliable 
and accurate INR values when compared to traditional laboratory 
methods.22 The World Health Organisation (WHO) recommended 
inclusion of plasmas from patients with INRs 1.5- 4.5 for calibration 
of a thromboplastin's ISI.23 Thus, the INR system is strictly valid up to 
an INR of 4.5. However, higher INRs are measured to assess bleeding 
risk and guide appropriate management.24 A study of 312 patients 
on warfarin showed that INRs > 4.5 with the CoaguChek XS Plus 
were comparable to laboratory INRs.25 Patient self- management 
(PSM) reduces the risk of mortality and VTE, but probably has no 
influence on the risk of major bleeding, and patient self- testing (PST) 
possibly reduces the risk of VTE and major bleeding.26 Accordingly, 
the American Society of Hematology (ASH) recommends PSM over 
F I G U R E  1  Summary of coagulation mechanisms and targets for action of different anticoagulants. Abbreviations: AT, antithrombin; 

































UFH/AT complex inactivating factors XIa, IXa, Xa, IIa 
Direct anti-Xa inhibitors (apixaban, betrixaban, edoxaban, rivaroxaban) 
Indirect anti-Xa inhibitors (UFH, LMWH, fondaparinux, danaparoid) 
Direct thrombin inhibitors (dabigatran, argatroban, bivalirudin) 
Vitamin K antagonists (e.g. warfarin) inhibiting post-translational y-carboxylation of glutamate residues to
y-carboxyglutamate in coagulation factors II, VII, IX and X and naturally occurring anticoagulants protein C and protein S
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any other management approach, and suggests PST over any other 
INR testing approach except for PSM, for suitable patients on main-
tenance VKA for VTE.26 British Society for Haematology (BSH) guid-
ance for health- care professionals exists on PST/PSM.27
3.3  |  Activated partial thromboplastin time (aPTT)
The aPTT is sensitive to the activity of coagulation FI, II, V, VIII, IX, X, 
XI, and XII. It can thus be used to monitor the anticoagulant effect of 
agents that reduce the activity of these factors, if a therapeutic range 
can be established. Baseline aPTT prolongation in an acute situation 
should prompt assessment of fibrinogen to investigate acute phase, 
and together with assessment of D- dimer, to check for disseminated 
intravascular coagulation. C- reactive protein (CRP) interferes with 
the aPTT, prolonging clotting times proportional to CRP concentra-
tion and depending on the type of the aPTT reagent.28 Raised levels 
of FVIII, an acute phase reactant, lead to aPTT shortening.29
3.4  |  Thrombin time (TT) modifications
The TT measures the conversion of fibrinogen to fibrin following ad-
dition of thrombin. The protamine sulphate neutralization assay, a 
TT- based assay, can be used to calculate the plasma concentration of 
UFH. Protamine titration produces reliable and reproducible results, 
but is not generally undertaken in modern hemostasis laboratories, 
as it is not readily automated30 and has been superseded by anti- Xa 
assays. In the dilute TT (dTT), a simple, rapid, sensitive, quantitative 
method, patient sample is diluted with normal plasma prior to the 
addition of thrombin. The dilution eliminates most interferences on 
the assay including factor deficiencies, D- dimer, and LA.
3.5  |  Chromogenic factor X (CFX)
The CFX activity is an alternative assay to the PT- INR. There is an 
inverse linear relationship between CFX and INR18,19; a CFX range of 
23.5% to 35.5% is suggested to be therapeutic (INR range 2.0- 3.0), 
with the lower CFX limit corresponding to an INR of 3.0.31 CFX as-
says showed poor utility for INR values ≥ 3.5 in non- APS patients, 
possibly due to interference by acarboxy- FX when the level of fully 
functional FX becomes very low, ≤12.0%.18 Therapeutic ranges for 
CFX are not established, and the assay is not well standardized, nor 
widely available or practicable for routine use.
3.6  |  Clotting factor II and X (FII and FX)
PT- based clotting assays for FII and X have been proposed as alter-
natives to the INR. Plasma concentrations of FII and X were propor-
tional to increases in INR in patients on warfarin, for INRs 2.0 to 3.5. 
However, for INRs > 3.5, a non- proportional relationship was found 
between INR and both factors. The authors suggested that below 
critical clotting factor concentrations (20.6% and 15.6% for factors 
II and X activity, respectively), the time required for clot formation 
becomes non- proportional and hemostasis will be jeopardized.32
3.7  |  Chromogenic anti- Xa or anti- IIa activity
Measurement of anti- Xa or anti- IIa activity is the preferred method 
when quantitative information is useful. Reference ranges for anti-
 Xa levels depend on the anticoagulant in use, the type, dose, sched-
ule, and indication. Monitoring is based on peak levels, with the 
timing of these depending on the half- life of the anticoagulant, and/
or trough levels.33 The anti- Xa assay has important advantages, in-
cluding that it is unaffected by raised CRP or FVIII related to an acute 
phase reaction; however, it has limitations, including considerable 
inter- laboratory variation34 and inter- assay variability.35,36
3.8  |  Ecarin based assays
Ecarin is a metalloprotease from the saw- scaled viper, Echis cari-
natus, that converts prothrombin to meizothrombin, which can be 
inhibited by direct thrombin inhibitors, but not heparin.37 The accu-
racy of the ecarin clotting time (ECT) may be impacted by fibrinogen 
and prothrombin deficiencies. The ecarin chromogenic assay (ECA) 
pre- dilutes the patient sample with a buffer containing prothrombin 
to minimize the prothrombin factor limitation; and, as it not a clot- 
based assay, it is not influenced by fibrinogen levels.37
3.9  |  Thrombin generation (TG)
TG assesses overall functional coagulation status of plasma and 
the dynamic processes of thrombin generation. The TG curve is 
quantified in terms of the lag time, time to peak TG, peak TG, and 
endogenous thrombin potential (ETP), which is the area under the 
curve.38 Increased ex vivo TG is a marker of thrombogenic poten-
tial and has predictive value for recurrent VTE.39 TG assays remain 
limited to specialized laboratories, and standardized protocols and 
data normalization should lead to better reproducibility and ability 
to compare data from different laboratories.40 A more standard-
ized automated TG method has become available: the ST Genesia 
(Diagnostica Stago, Asnières sur Seine Cedex, France).41 TG is not 
currently suitable for anticoagulant monitoring, as it is not standard-
ized and no therapeutic ranges have been established.
4  |  WARFARIN AND OTHER VITAMIN K 
ANTAGONISTS
Warfarin or an alternative VKA is the standard anticoagulation 
treatment for thrombotic APS.12- 14 Standard- intensity VKA (target 
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INR 2.5, range 2.0- 3.0) is used following a first VTE. The optimal 
anticoagulation intensity for APS- related arterial thrombosis is 
not defined or agreed, as existing data are not conclusive.13,14,42,43 
Recommended options include standard- intensity VKA, with or 
without LDA or high- intensity VKA, target INR 3.5 (range 3.0- 4.0), 
considering the individual's risk of bleeding and recurrent throm-
bosis.13,14, Should recurrent thrombosis occur while on standard- 
intensity VKA, other therapeutic options may include an increased 
target INR range, treatment dose LMWH, or the addition of anti-
platelet therapy.12- 14
Warfarin should be used with caution in patients with aPL- 
related thrombocytopenia, in view of its long half- life of 26 to 
48 hours;44 split- dose LMWH, half- life approximately 4 hours 
after subcutaneous injection,45 should be considered instead. The 
prevalence of thrombocytopenia (platelets < 100 x 109/L) was 
26.9% in 1000 APS patients in the Euro- Phospholipid project.46 










- Standard method to monitor VKA anticoagulation intensity in APS patients
- PT- INR raised in subset of APS patients (effect of LA on thromboplastin)
- Most thromboplastins: low sensitivity to LA with instrument- specific ISI
- Check new thromboplastins for sensitivity to LA before use to monitor VKA
- Local INR calibration to minimize between- laboratory INR variation
- Check baseline PT prior to anticoagulation wherever possible









- Several POC coagulometers available
- Reliable and accurate INRs compared to lab INRs in general population
- Variable POC INR results in APS patients
- Divergence between POC and lab INRs increases as INR values rise
- Interpret POC INR results with caution in APS patients17
- Pragmatic approach: check for concordance between POC and venous lab INRs 
initially and every 6- 12 months; use POC if INR difference is < 0.5
- Ensure regular IQC: if liquid IQC samples are available, they should be run at least 
when testing with a new batch of test strips or if an unexpectedly high or low result 
occurs, and at least once every 6 months (2C)27
- Ensure regular EQA which should take place at least every 6 months (2C)27
Chromogenic FX (CFX)
Chromogenic assay
- CFX range of ~ 20- 40 
% ≅
INR range of 2.0- 3.0
- Therapeutic ranges 
not established
- CFX provides an LA- independent measure of anticoagulation intensity
- Inverse linear relationship between CFX and INR; therefore, may provide a guide to 
anticoagulation intensity18,19
- Poor utility of CFX at INRs > 3.0 (when functional FX ≤ 12.0 IU/dL)18
- Therapeutic ranges are not established, and the assay is not well standardized, nor 
widely available or practicable for routine use
- Notwithstanding its limitations, CFX could assist in monitoring LA- positive APS who 
have a prolonged PTs prior to commencement of VKA or who experience recurrent 
VTE while on apparently therapeutic VKA anticoagulation
Coagulation factor II and 
X assays
Clotting assays
Therapeutic ranges not 
established
- Coagulation FII and X levels proportional to INRs between 2.0- 3.5 in general 
population patients32
- Non- proportional relationship at INR > 3.532
- Unclear whether useful for VKA monitoring in APS
- FII coagulation assay not applicable for monitoring VKA anticoagulation in patients 





Therapeutic ranges not 
established
- ETP and peak TG show significant inverse correlations with INR in non- APS and APS 
patients, including in those with INR ≥ 3.518
- Concordance with in vivo coagulation activation markers being normal in most non- 
APS and APS patients with VTE who have an INR ≥ 2.069,71
- A subgroup of APS patients with increased peak TG, despite therapeutic INR and CFX, 
suggests that TG might identify an ongoing prothrombotic state18
- The use of TG remains limited to specialized laboratories due to lack of standardization 
and no established therapeutic ranges
Abbreviations: APS, antiphospholipid syndrome; CFX, chromogenic factor X; EQA, external quality assessment; ETP, endogenous thrombin potential; 
INR, international normalized ratio; ISI, international sensitivity index; IQC, internal quality control; LA, lupus anticoagulant; MNPT, mean normal 
prothrombin time (geometric mean of the prothrombin times of the healthy adult population); POC, point- of- care; PT, prothrombin time; TG, 
thrombin generation; VKA, vitamin K antagonist.
aSee text regarding use of high- intensity VKA. 
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Thrombocytopenia appears to be associated with higher throm-
botic risk in APS patients with platelets < 150 x 109/L, with a 
reported hazard ratio (HR) of 2.95, 95% confidence interval (CI) 
1.11- 7.88.47 The risk of teratogenicity with VKAs is extremely low, 
provided that women are switched from VKA to LMWH before 6 
weeks of gestation.48
4.1  |  Anticoagulant monitoring of VKAs in APS
The PT- INR is traditionally used to monitor VKA anticoagulation 
intensity. LA- induced PT prolongation, typically unassociated with 
bleeding, is unusual, likely due to the high phospholipid concentra-
tion in PT reagents (Table 1). Use of an instrument- specific ISI re-
duced the differences observed between reagents in earlier studies, 
for samples with INRs within the therapeutic range, with similar 
results in APS and non- APS patients.49 A multicenter study demon-
strated that differences in PT- INR when measured with the major-
ity of commercial thromboplastins are not enough to cause concern, 
if thromboplastins insensitive to LA and instrument- specific ISI 
calibration are used19. Recombinant thromboplastins produce con-
sistently higher INRs,19 which could potentially alter clinical man-
agement.18 New thromboplastins should be checked for sensitivity 
to LA.17 LA can prolong the PT when associated with the rare LA- 
hypoprothrombinemia syndrome with acquired factor II deficiency, 
caused by anti- prothrombin antibodies.50 Despite its limitations for 
monitoring VKA- treated APS patients, the INR remains in general 
use.
POC INR testing, however, shows variable results in APS pa-
tients. A study of 29 APS versus 31 non- APS patients using the 
ProTime InRhythmTM System (finger stick or venous non- citrated 
blood) showed a difference of < 0.4 INR units compared to venous 
citrated blood laboratory INR (both measured with human recombi-
nant thromboplastin) in 97% of patients, suggesting that this device 
is accurate in APS- and non- APS patients.51 However, in a compar-
ative study, 5/59 (8%) patients with APS and both elevated aβ2GPI 
and LA had non- measurable ProTime® INR results and generally 
higher HemochronTM Signature INR results than the plasma- based 
INR, indicating elevated POC INRs in a subset of APS patients. The 
divergence between POC and laboratory INRs increased as INR val-
ues rose.52 Taylor et al found that the mean INR difference between 
the CoaguChek XS and laboratory INR was 0.68, with a difference 
significantly higher in APS patients than in controls with a target 
INR of 2 to 3.53 Isert et al did not observe a higher disagreement 
between INR results from CoaguChek versus laboratory INR, using 
two thromboplastins, in APS patients.54 However, INR variations 
above 0.5 were more frequent in APS patients compared to controls 
(55.6% vs. 67.8%, P = .05). No in- depth analysis has been performed 
to identify the reason for variability in INR by POC devices com-
pared to plasma- based laboratory INR in APS patients, or the reason 
for variability between POC devices. More investigation to unravel 
potential differences in PT- INR measured in APS patients by POC 
devices is needed.
Pending further data to establish the place of POC INR testing 
in LA- positive patients, results should be interpreted with caution.17 
A pragmatic approach is to restrict POC testing to APS patients 
in whom concordance of POC and laboratory INRs (INR differ-
ence < 0.5 units) is demonstrated at therapeutic intensity initially 
and every 6- 12 months; ensure regular internal quality control (IQC), 
and ongoing review of external quality assessment (EQA) results to 
check that concordance is maintained.27,55 It is prudent to apply this 
to all APS patients rather than only those who are LA- positive, as LA 
testing could yield false negative results, but might influence INR 
monitoring.
CFX provides an LA- independent assessment of VKA anticoagu-
lant intensity. This is because the CFX assay requires minimal phos-
pholipid, and the initial dilution is large, which would make the assay 
less sensitive to LA.31 A literature review of CFX use that selected 
9/55 articles for their relevance, concluded that in a subgroup of APS 
patients, INRs may be falsely elevated and thus may not accurately 
inform the dose of warfarin.56 Notwithstanding its limitations, CFX 
could assist in monitoring LA- positive APS patients, particularly in 
those who have a prolonged PT prior to commencement of VKA or 
who experience recurrent VTE while on apparently therapeutic VKA 
anticoagulation.
A study of concurrent INR, CFX, and PT- based clotting FII lev-
els in 36 patients (26 aPL positive), showed limited discordance be-
tween CFX and FII. The authors concluded that FII and CFX testing 
are well correlated in patients in whom anticoagulation with warfarin 
requires alternative monitoring to INR and thus that either test can 
be used in this population.57 In contrast to the study of Rosborough 
et al that showed, in 14 of 21 LA- positive patients, a significantly 
lower FII/CFX ratio than in LA- negative patients,58 Baumann 
Kreuziger et al did not find a difference in FII/CFX ratios between 
patients with or without LA.57 FII (clotting or chromogenic) assays 
should be avoided for anticoagulant monitoring in APS patients with 
LA- hypoprothrombinemia syndrome.50
ETP and peak TG parameters showed significant inverse correla-
tions with INR in APS patients on warfarin, including those with ≥ 3.5 
INR, suggesting that TG might inform anticoagulant intensity in pa-
tients on high- intensity VKA.18 Additionally, increased peak TG in a 
subgroup of APS patients, despite therapeutic INR and CFX, suggests 
that TG might be able to identify an ongoing prothrombotic state in 
VKA- treated patients.18 The normalized TG- derived peak height/lag 
time ratio identifies LA in plasma with high sensitivity, irrespective of 
the patient’s treatment with oral anticoagulants, if TG is performed 
on mixtures of patient plasma and pooled normal plasma.59
5  |  DIREC T OR AL ANTICOAGUL ANTS 
(DOAC S)
Current first- line anticoagulation used for a first episode of VTE in 
the general population is a DOAC.60 Post hoc analysis of the RE- 
COVER, RE- COVER II, and RE- MEDY randomized controlled trials 
(RCTs) suggested that the efficacy and safety of dabigatran etexilate 
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TA B L E  2  Monitoring tests, expected peak and trough concentrations of direct oral anticoagulants for treatment of venous 
thromboembolism (adapted from Gosselin et al)37 and examples of other medications or supplements to use with caution113
Dabigatran Rivaroxaban Apixaban Edoxaban
Standard dose 150mg bd 20mg od 5mg bd 60mg od
Monitoring test - Dilute thrombin time
- Ecarin clotting time
- Ecarin chromogenic 
assay


























Examples of medications 
contraindicated: 
strong inhibitors of 
both CYP3A4 & P- gp 
pathways
- systemic azole 
antifungalse 
- strong CYP3A4 
inducersf 
- HIV protease 
inhibitorsg 
- systemic azole 
antifungalse 
- strong CYP3A4 inducersf 
- HIV protease inhibitorsg 
- systemic azole 
antifungalse 
- strong CYP3A4 
inducersf 
- HIV protease 
inhibitorsg*
- systemic azole antifungalse 
- strong CYP3A4 inducersf 
- HIV protease inhibitorsg 
Examples of medications 




- SSRIsh  or SNRIsi 




- SSRIsh  or SNRIsi 




- SSRIsh  or SNRIsi 




- SSRIsh  or SNRIsi 
- omega 3 fish oils
– ginkgo biloba
Comments
- Renal function, liver function, and full blood counts should be checked at baseline, at least annually, and more frequently as clinically indicated
- DOAC levels should be measured in patients who weigh > 120kg as recommended in ISTH guidance,114 although a recent report suggests that 
standard rivaroxaban dosing is suitable at extremes of body weight, <50kg to 150kg115
- Other populations when DOAC monitoring could be clinically useful include: in the elderly, those at extremes of body weight, those requiring 
drugs that impact certain metabolic pathways, those with renal impairment (CrCl [C&G] is < 30 mL/min); when an interacting medication is 
prescribed; when there is doubt around oral absorption, to assess adherence68,116
- Moreover, DOAC- treated patients that require acute intervention or in emergent situations, such as bleeding, overdose, acute stroke, trauma, 
surgery, may require assessment of their coagulation status to assure appropriate management68,116
- For most of these scenarios, it is the clearance of the DOAC that is of interest, so trough concentrations are prioritized, except in the case of a 
bleeding emergency or to confirm oral absorption116
http://www.kings throm bosis centre.org.uk/index.php/antic oagul ation/ antic oagul ation - monit oring
- DOAC levels should be measured if testing for LA (as DOACs may cause false positives and negatives), after the DOAC has been stopped for at 
least 48 hours and longer if there is renal impairment69
- Alternatively, LA can be measured after preanalytical neutralizing or adsorbing DOAC70
- LC- MS/MS is considered the gold standard method for the measurement of DOACs. However, it is not widely available, and is time consuming, 
expensive, and requires a high level of expertise. Therefore, tests that are more accessible have been developed, based on existing methods
Drug- specific calibrator should be used for anti- Xa and IIa assays and results expressed in mass concentration: ng/mL
- Antithrombin supplement anti- Xa methods should not be used for DOAC assessment
- Ecarin clotting time can be affected by hypoprothrombinaemia due to anti- prothrombin antibodies
- Ecarin chromogenic assay has prothrombin added and is less sensitive to factor deficiencies
- DOACs should be used with caution in patients with APS- associated thrombocytopenia
- Anti- Xa inhibitors and dabigatran are contraindicated in Europe at creatinine clearance (C&G) < 15 mL/min and < 30 mL/min, respectively, with 
dose reductions for renal impairment, following the SmPC recommendations.
Abbreviations: bd, twice daily; C&G, Cockcroft and Gault; CrCl, creatinine clearance; HIV, human immunodeficiency virus; IQR, interquartile range; 
LC- MS/MS, liquid chromatography with tandem mass spectrometry; NSAIDS, non- steroidal anti- inflammatory agents; SmPC, summary of product 
characteristics; SNRI, selective noradrenaline receptor inhibitor; SSRI, selective serotonin receptor inhibitor; VTE, venous thromboembolism.
aMean (25th– 75th centile). 
bMean (5th– 95th centile). 
cMedian (5th– 95th centile). 
dMedian (IQR). 
eeg, ketoconazole, itraconazole, voriconazole and posaconazole. 
feg, rifampicin, phenytoin, carbamazepine, phenobarbital or St. John's Wort. 
geg, ritonavir; *reduce dose by 50%. 
hcitalopram. 
ieg, duloxetine and venlafaxine; *These agents, which should be used with caution in patients on any anticoagulant, inhibit platelet function and 
potentially increase bleeding risk. 
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were not significantly affected by the presence of aPL,61 with no 
analogous data available for the other DOACs.
The European Medicines Agency (EMA), following a risk as-
sessment triggered by the TRAPS (Rivaroxaban in Thrombotic 
APS) RCT,62 stated that DOACs are not recommended for throm-
botic APS patients, especially those who are triple aPL- positive.63 
The ISTH12 and 16th International Congress on Antiphospholipid 
Antibodies Task Force Report on APS Treatment Trends13 con-
cur in recommending that in single- or double aPL- positive APS 
patients following a first VTE, DOACs initiated as standard care 
may be continued, with consideration of the perceived risks and 
uncertainties and discussion with the patient, for shared decision- 
making. The doses of DOACs used in APS patients reported in 
the literature have been shown to be as effective as warfarin at a 
target INR range of 2.0 to 3.0 in general- population patients fol-
lowing a first VTE. These DOAC doses may not be sufficient to 
prevent further thrombosis in APS patients who experience re-
current thrombosis while on therapeutic- intensity VKA or those 
with a history of arterial thrombosis.64 Notably, in animal mod-
els, stronger inhibition of Xa activity is required to protect against 
arterial versus venous thrombosis,65 although clinical studies are 
lacking. DOACs should be avoided in patients with APS- related 
arterial or small vessel thrombosis (proven or suspected),12,13 ex-
cept in the context of a clinical trial. The RISAPS (Rivaroxaban 
for Stroke Patients with Antiphospholipid Syndrome) phase 2/3 
RCT aims to assess the efficacy of high- intensity rivaroxaban 
15mg twice daily versus high- intensity warfarin in APS patients 
with stroke or other brain ischaemic injury (ClinicalTrials.gov 
Identifier: NCT03684564). All cases of DOAC use in APS patients 
should be reported to the ISTH- supported international registry 
(ClinicalTrials.gov Identifier: NCT04262492).12,13
The teratogenic risk of DOACs in humans is uncertain, estimated 
to potentially affect 2.2% (7/137) pregnancies.66 ISTH guidance rec-
ommends that DOACs are switched to an alternative anticoagulant 
pre- conceptually, with the main options VKAs (to be switched to 
LMWH as soon as possible when pregnant and before 6 weeks ges-
tation), or LMWH.67
5.1  |  Anticoagulant monitoring of DOACs in APS
As in non- APS patients, DOAC anticoagulant effect is not routinely 
monitored, but there is increasing demand on the laboratory to have 
the capacity to adequately assess DOAC anticoagulant effect (pharma-
codynamics) or levels (pharmacokinetics) in emergent or routine situa-
tions (Table 2).68 DOAC levels should also be measured if testing for LA 
(as they may cause false positives and negatives), after the DOAC has 
been stopped for at least 48 hours and longer if there is renal impair-
ment.69 Alternatively, LA can be measured after preanalytical neutral-
izing or adsorbing DOAC.70 As with VKAs, DOACs should be used with 
caution in thrombotic APS patients with thrombocytopenia, particu-
larly as based on their half- lives,37 DOAC anticoagulant effects persist 
for > 48 hours; LMWH should be considered instead.
Drug- calibrated chromogenic anti- Xa assays are suitable to pro-
vide quantitation of direct anti- Xa inhibitors33,37,68 in APS patients. 
Drug- calibrated dTT and anti- FIIa chromogenic methods are suit-
able ways to provide quantitation of dabigatran.33,37,68 The ECT, 
also generally suitable to monitor dabigatran, should not be used in 
patients with LA- hypoprothrombinemia syndrome.50 The ECA has 
prothrombin added and therefore could be used in this context.
TG has been found to be sensitive to all kinds of anticoagulants 
and may best represent inter- individual response more so than ex-
ploring merely plasma drug concentrations.68 In non- APS patients 
with VTE, rivaroxaban was reported to provide effective anticoag-
ulation, as assessed by inhibition of TG and in vivo markers of co-
agulation activation.71 Notably, reduced TG parameters have been 
reported to persist at 12 hours after DOAC intake, despite low resid-
ual DOAC plasma levels < 50 ng/mL.72 In the RAPS (Rivaroxaban in 
Antiphospholipid Syndrome) RCT in APS patients with VTE requiring 
standard- intensity anticoagulation, the primary outcome, percent-
age change in ETP for rivaroxaban, did not reach the non- inferiority 
threshold. However, peak thrombin was significantly lower on ri-
varoxaban and the authors concluded that the overall TG curve, in 
which the higher ETP reflects the altered reaction kinetics with ri-
varoxaban, was not indicative of increased thrombotic risk.73
A more standardized method for TG measurement has become 
available recently: the ST Genesia (Diagnostica Stago, Asnières sur 
Seine Cedex, France), an automated analyzer for TG. This may be a 
“game changer” for the assessment of DOAC anticoagulant effects 
in the future.68 TG parameters measured with ST Genesia correlate 
with drug levels of anti- Xa DOACs. Peak thrombin and velocity index 
are of special interest for the determination of residual anticoagulant 
effect at low drug levels. For dabigatran- treated patients, only lag 
time shows a correlation with the dabigatran plasma levels.74 As with 
VKAs, TG is not currently suitable to monitor anticoagulant intensity 
in DOAC- treated APS patients.
6  |  LOW MOLECUL AR WEIGHT HEPARIN
LMWH is used as initial bridging anticoagulation in patients treated 
with VKA24 and as initial and bridging anticoagulation when recurrent 
thrombosis occurs on standard- intensity VKA, ongoing options includ-
ing high- intensity VKA or treatment dose LMWH.12- 14 Should throm-
bosis recur while on high- intensity VKA, or standard- treatment dose 
LMWH, ie, anticoagulant- refractory thrombotic APS, high- intensity 
and subsequently escalated high- intensity LMWH, approximately 
one- quarter and one- third above standard intensity dose LMWH, 
respectively, may be considered.42,75,76 LMWH can provide bridging 
anticoagulation peri- operatively in VKA- treated patients, because 
of its relatively short half- life.45 The risk of heparin- induced throm-
bocytopenia (HIT) with LMWH is considered low (<0.1%) in medical 
and obstetric patients, after minor surgery or minor trauma, and in-
termediate (0.1%- 1.0%) following major surgery or major trauma.77 
Prolonged LMWH use, between 3 and 24 months, decreases mean 
bone mineral density (BMD) by 2.8% to 4.8% (depending on the site) 
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versus 1.2% to 2.5% with VKA.78 The International Congress on 
Antiphospholipid Antibodies Task Force Report on APS Treatment 
Trends has recommended that vitamin D deficiency is corrected in 
APS patients, based on general population guidelines.13 As indicated 
above, LMWH should be considered rather than VKA or DOACs in 
thrombotic APS patients with thrombocytopenia.
LMWH or UFH do not cross the placenta. The optimal dose regi-
men for LMWH during pregnancy in thrombotic APS is not established. 
A history of thrombotic APS is associated with increased risk for future 
thrombotic events;79 thus, therapeutic dose heparin, together with 
LDA, during pregnancy appears prudent, as per the recommendation in 
the European League Against Rheumatism (EULAR) guidelines.14 The 
United Kingdom Royal College of Obstetricians and Gynaecologists 
(RCOG) guidelines, in alignment with other national guidelines, do not 
recommend routine anti- Xa monitoring during pregnancy in patients 
on LMWH except in certain circumstances: < 50 kg or > 90 kg or with 
other complicating factors, for example with renal impairment or re-
current VTE.85 The optimal dosage regimen of LMWH for treatment of 
VTE in pregnancy (once daily versus split- dosing, ie, two divided doses) 
and the value and role of anti- Xa monitoring merits further investiga-
tion.85 Limited data suggest that patients with a history of APS- related 
cerebrovascular events are at excess risk of recurrence during preg-
nancy,80,81 thus high- intensity adjusted dose LMWH may be warranted.
6.1  |  Anticoagulant monitoring of LMWH in APS
The aPTT is not usable for LMWH monitoring (Table 3). The aPTT will 
be variably prolonged at peak levels, and often only shows a mild pro-
longation over that due to the LA, depending on the sensitivity of the 
individual reagents used for LMWH and LA.82 The anti- Xa chromogenic 
assay, unaffected by LA, is the most appropriate assay for monitoring 
LMWH in APS patients, as in non- APS patients. Evidence on LMWH 
dosing and monitoring in APS is lacking and may be extrapolated from 
use in general population patients. Dose reduction of LMWH, follow-
ing the manufacturer's summary of product characteristics, should be 
undertaken in accordance with the SmPC in APS patients with creati-
nine clearance (CrCl; Cockcroft- Gault [C&G]) <30mL/min, with anti- Xa 
monitoring considered to check for accumulation. The most appropri-
ate LMWH dosing in patients with obesity remains undefined.83
LMWH dosing should be adjusted for APS- associated thrombo-
cytopenia. Therapeutic dosing in thrombocytopenic APS patients 
may be extrapolated from use in other thrombotic situations, such 
as in cancer patients. ISTH guidance recommends full- dose antico-
agulation following acute VTE in cancer patients with a high risk of 
thrombus propagation and a platelet count > 50 x 109/L and advise 
platelet transfusion support in those with thrombocytopenia to 
maintain platelet counts of 40- 50 x 109/L.84 In APS patients, immu-
nomodulatory treatment may increase platelet counts sufficiently 
for therapeutic anticoagulation. Platelet counts should be monitored 
while on LMWH, during the first 14 days in patients at intermediate 
risk for HIT,77 and beyond, to guide consideration of dose reduction, 
if required, for secondary thromboprophylaxis.
The optimal dosage regimen of LMWH for treatment of VTE in 
pregnancy (once daily versus split- dosing, ie, two divided doses) and 
the value and role of anti- Xa monitoring merits further investigation.85
7  |  UNFR AC TIONATED HEPARIN (UFH)
UFH has a shorter half- life than LMWH (60 minutes after an intra-
venous (IV) bolus of 100 units/kg)45 and may be preferred for an-
ticoagulation in situations in which bleeding risk is high, and rapid 
reversal of heparin effect by protamine sulphate45 may be required, 
such as in patients with CAPS associated with severe thrombocy-
topenia (platelets < 20 x 109/L),86 or those who may need urgent 
critical site surgery. In the CAPS Registry, the majority of patients, 
403 of 471 (85.6%), were treated with anticoagulation, which was 
usually IV UFH followed by oral anticoagulation. UFH has been rec-
ommended for use in CAPS, based on a meta- analysis of two stud-
ies including 325 CAPS registry patients, which showed significantly 
lower mortality in anticoagulated patients (odds ratio [OR] 0.18; 95% 
CI, 0.09, 0.38; with very low certainty of evidence).16 UFH is also 
standard treatment during cardiopulmonary bypass (CPB) surgery.87
UFH may be associated with a higher risk of bleeding compared 
to LMWH. A meta- analysis of 13 RCTs of LMWH versus UFH for VTE 
treatment showed no difference in risk for major bleeding (relative risk 
[RR] 0.63 [95% CI, 0.37- 1.05]).88 However, an observational cohort 
study on 3066 hospitalizations of adults receiving therapeutic doses 
of UFH and LMWH over a year showed in multivariate analysis that 
UFH was a significant predictor of bleeding (OR 2.35, 95% CI 1.11- 
4.98; P = .005).89 The risk of HIT with UFH is considered intermediate 
(0.1- 1%) in medical and obstetric patients, and high (>1.0) in surgical 
and trauma patients receiving postoperative UFH,77 which is a disad-
vantage compared to LMWH. A prospective matched cohort study in 
50 patients reported that UFH therapy for more than 1 month during 
pregnancy was associated with a significant reduction in bone density, 
although fractures were uncommon, with no significant correlation 
between lumbar bone density and the dose or duration of heparin.90
7.1  |  Anticoagulant monitoring of UFH in APS
Monitoring of therapeutic doses of intravenous UFH is recom-
mended and can be achieved using an anti- Xa assay or an aPTT 
with a therapeutic range corresponding to 0.3 to 0.7 IU/mL anti- Xa 
activity (Table 3).33,45 The aPTT is typically prolonged in APS, par-
ticularly if reagents sensitive to LA are used. Thus, for UFH moni-
toring by aPTT, a relatively LA- insensitive aPTT reagent should be 
used.33,69 If the baseline aPTT is prolonged, the aPTT should not 
be used for UFH monitoring as this may overestimate heparin ef-
fect, resulting in subtherapeutic anticoagulation and a potentially 
increased risk of recurrent thromboembolism. BSH guidelines 
state that the anti- Xa assay could be the test of choice to moni-
tor UFH.33 There are great advantages to use of the chromogenic 
anti- Xa assay instead of the aPTT in all cases in which a prolonged 
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(Continues)









- Standard treatment dose 
(once daily)
- Standard treatment dose 
(twice daily dosing, i.e., 
split- dose)
- High/escalated- intensity 
LMWH ~ 25% or 33% 
above standard dose, 
respectively (twice daily 
dosing)
- No routine anti- Xa 
monitoring
- Peak anti- Xa 0.5- 1.0 
IU/mL
- Peak anti- Xa 1.0- 1.2 
IU/mL
- LA- independent measure of anticoagulant activity
- Standard therapeutic dose LMWH with weight- based dosing, 
without anti- Xa monitoring, applies in most cases
- Peak anti- Xa should be monitored 4 hours after dosing as levels 
peak at 3- 5 hours
- The therapeutic range for standard therapeutic dose LMWH 
administered twice daily is generally regarded to be 0.5 to 1.0 
IU/mL80,117
- A high- intensity anti- Xa therapeutic range, based on twice daily 
dosing, of 1.0- 1.2 IU/mL, is reasonable
- Empirical dose reduction of LMWH if CrCl (C&G) <30mL/min 
and/or anti- Xa (trough [maintain < 0.3units/mL] and peak) 
monitoring, following SmPC
- Ensure adequate LMWH doses in obese patients, consider anti- Xa 
monitoring
- Consider twice daily dosing if increased bleeding risk, eg, CrCl 
(C&G) <30mL/min; thrombocytopenia; and during pregnancy
- Dose reduction for treatment and secondary thromboprophylaxis 
for thrombocytopenia (see text)
- The optimal dosage regimen and monitoring during pregnancy is 
undefined (see text)85
- Monitor platelets for HIT in patients receiving LMWH after major 
surgery or major trauma77
- HIT monitoring not suggested during LMWH use in medical 




- IV bolus of UFH 5000 units /
75 units/kg (10,000 units for 
severe PE)
- then 15- 25 units/kg/hour, 





to UFH levels 
of 0.3 to 0.7 IU/
mL anti- Xa 
activity33,45
- For continuous UFH by IVI, samples for anticoagulant monitoring 
should be collected 4- 6 hours after initiation and thereafter at 
least daily and after dose adjustment33
- For UFH monitoring by aPTT, a relatively LA insensitive APTT 
reagent should be used33,69
- aPTT therapeutic range should be locally adapted to the 
responsiveness of the reagent and coagulometer used45
- If the baseline aPTT is prolonged, the aPTT should not be used for 
UFH monitoring as this may overestimate heparin effect
- The aPTT may be unreliable in the acute phase situation
- Perform anti- Xa level to distinguish real from apparent “heparin 
resistance,” ie, daily dose > 35,000 units; interpret results in the 
context of concomitant APTT
- In all patients on UFH, monitor platelet counts for HIT, including in 






- The anti- Xa assay instead of the aPTT should be used in all cases 
in which a prolonged baseline aPTT is suspected; this would 
include LA positive patients
- Particularly in view of the potential for unreliable aPTTs due to to 
LA- induced effects and patient safety issues as a result, anti- Xa 
rather than the aPTT is more appropriate to monitor UFH in 
APS patients
- The anti- Xa assay has important advantages, including that it is 
unaffected by raised CRP or FVIII related to an acute phase 
reaction
- In CAPS patients in the acute phase situation, use anti- Xa to 
monitor UFH; interpret results in the context of concomitant 
aPTT
- An UFH reference standard traceable to the current International 
Standard for UFH should be employed for estimation of UFH in 
IU/mL if an anti- Xa assay is used for monitoring33
- Limitations of anti- Xa assays include that they are more complex 
to perform than the aPTT and not universally available
- Further limitations include considerable inter- laboratory 
variation34 and inter- assay variability.35,36
902  |    COHEN Et al.
baseline aPTT is suspected; this would include LA positive patients. 
Particularly as aPTTs may be unreliable due to LA- induced effects 
and the potential for patient safety issues as a result, anti- Xa rather 
than the aPTT is more appropriate to monitor UFH in APS patients.
Unusually high doses of UFH may be required to achieve a thera-
peutic aPTT, ie, “heparin resistance,”45 in the acute situation such as 
in CAPS, with potential mechanisms including raised levels of FVIII 
and fibrinogen, and other heparin- binding acute phase reactants, 
which lead to aPTT shortening91 Decreased antithrombin levels are 
also associated with “heparin resistance,”92 reported to be reversed 
by supplementation with antithrombin concentrate in patients un-
dergoing cardiac surgery.93 Anti- Xa levels, interpreted in the con-
text of concomitant aPTTs, are advised.86 Platelet counts should be 
monitored during UFH treatment and HIT considered should the 
platelet count fall.77
The activated clotting time (ACT), a phospholipid- dependent test 
widely used to monitor UFH during cardio- pulmonary bypass (CPB), 
may be prolonged by LA. There is no consensus in the literature re-
garding optimal anticoagulation for APS patients in this challenging 
situation. Reported approaches in CPB include targeting twice the 
baseline ACT, measuring heparin concentrations by an automated 
protamine titration device, using preoperative in vitro heparin- ACT 
titration curves, and also measuring heparin anti- Xa levels;94 and 
ACT coupled with thromboelastography.95
8  |  OTHER PARENTER AL ANTICOAGUL ANT 
OPTIONS IN THROMBOTIC APS PATIENTS
8.1  |  Fondaparinux
The specific anti- Xa activity of fondaparinux is seven times higher 
than that of LMWH (~700 units/mg and 100 units/mg, respectively), 
and its half- life after subcutaneous injection is longer than that of 
LMWH (17 and about 4 hours, respectively).45 The successful use of 
fondaparinux was reported in two patients with APS in combination 
with mycophenolate mofetil,96 and in three APS patients with recur-
rent thrombosis.97
The risk of fondaparinux- related HIT is low (<0.1%).77 In vitro 
studies show no significant inhibitory effect of fondaparinux on 
osteoblast proliferation or activity,98 although clinical data in this 
context are lacking. Fondaparinux has been reported to cross the 
placenta, resulting in low but measurable anti- Xa activity in umbilical- 
cord blood.85,99 A review of maternal and pregnancy outcomes of 65 
pregnancies in women using fondaparinux (11 on therapeutic dose) 
reported that it was well tolerated and the rate of pregnancy com-
plications was similar to that observed in the general population.100 
Fondaparinux is assigned to category B by the U.S. Food and Drug 
Administration (FDA), ie, that it should only be given during preg-
nancy when need has been clearly established (https://www.acces 
sdata.fda.gov/drugs atfda docs/label/ 2008/02088 3s014 lbl.pdf).
8.2  |  Anticoagulant monitoring of fondaparinux 
in APS
Fondaparinux dosing is weight based. It is nearly completely eliminated 
by renal clearance and therefore contraindicated in patients with 
severe renal impairment (CrCl [C&G] <30mL/min; Table 4). Routine 
anticoagulation monitoring is not recommended; however, it may be 
useful in some circumstances, such as after re- thrombosis while on 
fondaparinux to assess patient adherence to inform consideration of 
an escalated dose. Fondaparinux- specific anti- Xa assays are available, 
although a therapeutic anti- Xa range has not been established.
8.3  |  Direct thrombin inhibitors: argatroban and 
bivalirudin
Argatroban, half- life 45 minutes after intravenous (IV) injection,101 is 
not renally excreted and is therefore an option in patients with HIT 






UFH TT with 
protamine 
titration
- Superseded by anti- Xa assays
UFH ACT In non- APS patients 
undergoing CPB, generally 
a dose of UFH of ~ 300- 
400 IU/kg is administered 
prior to CPB with 
additional boluses given as 
required
In non- APS patients:
- ACT in a non- 
anticoagulated 
patient is ~ 107s ± 
13s - During CPB, 
UFH is titrated to 
maintain an ACT 
of 400- 600s
- The ACT is a phospholipid- dependent test widely used to monitor 
UFH during CPB
- The ACT may be prolonged by LA
- Suggested modification for use in APS: target clotting time twice 
the baseline ACT94
- Other suggested modifications:
(i) measure heparin concentrations by automated protamine 
titration device
(ii) use preoperative in vitro- derived heparin- ACT titration curves94
(iii) ACT coupled with thromboelastography95
Abbreviations: ACT, activated clotting time; aPTT, activated partial thromboplastin time; CAPS, catastrophic antiphospholipid syndrome; CrCl (C&G), 
creatinine clearance (Cockcroft and Gault); HIT, heparin- induced thrombocytopenia; IVI, intravenous infusion; LA, lupus anticoagulant; LMWH, low 
molecular weight heparin; SmPC, summary of product characteristics; TT, thrombin time; UFH, unfractionated heparin.
TA B L E  3  (Continued)
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TA B L E  4  Monitoring of anticoagulation in APS patients on fondaparinux, direct thrombin inhibitors (argatroban and bivalirudin) and 
danaparoid




Fondaparinux Anti- Xa Weight based
as per SmPC
(once- daily)
Not established - Routine anti- Xa monitoring not recommended
- Monitoring may be useful after re- thrombosis to assess patient 
adherence and inform consideration of high- intensity dose76
- Almost completely renally cleared, therefore contraindicated in 
severe renal impairment (CrCl [C&G] <30mL/min)
- The mean expected peak steady- state plasma concentration on 
once- daily therapeutic dose fondaparinux can be expected to 
be 1.20 to 1.26 mg/L 3 hours post dose45
- Consider twice daily dosing (on an empirical basis) if used 
in anticoagulant- refractory APS patient who is also on 
antiplatelet treatment, or if use high- intensity fondaparinux 
dose, to limit bleeding risk76
- Suggested option for HIT77
Argatroban - Dilute thrombin 
time





Continuous IV infusion, 
initial dose
1 to 2 mg/kg/min;
dose is adjusted to 
maintain therapeutic 
levels
Not established - Not renally excreted, therefore useful in APS patients with HIT 
and severe renal impairment, including CAPS
- Routinely monitored by aPTT; however, the aPTT could give 
unreliable results due to LA- induced effects, as well as those 
of raised CRP or factor VIII levels
- SmPC advises aPTT ratio between 1.5 and 3.0 but not exceeding 
100 seconds
- Metabolized by the liver via CP450 3A4/5; reduce dose to 
0.5mg/kg/min if hepatic dysfunction, critically ill, after 
cardiac surgery, heart failure
- Drug- calibrated chromogenic anti- IIa assays are suitable to 
monitor argabtroban
- When bridging with argatroban to warfarin in LA- positive 
patients, check CFX and stop argatroban when CFX < 45 
(equivalent to INR ~>2.0)
- Suggested option for HIT77
Bivalirudin - As for argatroban IV bolus of 0.1 mg/kg 
followed by an infusion 
of 0.25 mg/kg/hr
Not established - ~ 20% is renally excreted; consider dose reduction in patients 
with moderate to severe renal impairment45
- consider dose reduction in patients with hepatic dysfunction77
- aPTT ratio is the usual monitoring test, target range 1.5- 2.5 but 
could give unreliable results due to LA- induced effects
- Drug- calibrated chromogenic anti- IIa assays are suitable to 
monitor bivalirudin
- When bridging with argatroban to warfarin in LA- positive 
patients, check CFX and stop bivalirudin when CFX < 45 
(equivalent to INR ~ > 2.0)
- Suggested option for HIT77
Danaparoid - Anti- Xa Therapeutic dose as per 
SmPC, administered by 
continuous IVI
0.5- 0.8 U/mL - Contraindicated in severe renal and hepatic insufficiency, unless 
there is no alternative for HIT
- In general, anti- Xa monitoring not necessary
- Monitoring of anti- Xa activity is recommended in patients with 
renal insuffiency and/or if weight > 90kg
- Suggested option for HIT77
- Serological cross- reactivity with heparin- platelet factor 4 
antibodies ~ 5%, incidence of clinical cross- reactivity 
developing ~ 3%; SmPC advises monitoring platelets for HIT 
during treatment: https://www.medic ines.org.uk/emc/produ 
ct/5369/smpc
- Danaparoid is currently unavailable in the United States; 
however, it is available in several other countries including 
Canada, Australia, New Zealand, European countries and 
Japan
Abbreviations: APS, antiphospholipid syndrome; aPTT, activated partial thromboplastin time; CAPS, catastrophic antiphospholipid syndrome; CFX, 
chromogenic factor X; CrCl (C&G), creatinine clearance (Cockcroft and Gault); HIT, heparin- induced thrombocytopenia; IVI, intravenous infusion; 
SmPC, summary of product characteristics.
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the liver via the cytochrome P450 3A4/5 enzyme system and should 
therefore be used with caution in patients with hepatic dysfunc-
tion.101 Argatroban has been used successfully in case reports dur-
ing pregnancy;102,103 however, there are no controlled data in human 
pregnancy. Bivalirudin has a half- life of 25 minutes after IV injec-
tion.104 Approximately 20% is renally excreted and dose reduction 
should be considered in patients with moderate to severe renal im-
pairment(45) or hepatic dysfunction.77 Bivalirudin is suggested as an 
option in patients with acute HIT or subacute HIT (ie, normal plate-
lets, positive functional test for HIT) who require cardiovascular sur-
gery that cannot be delayed.77 Both argatroban and bivalirudin are 
assigned to category B by the FDA.
8.4  |  Anticoagulant monitoring of argatroban and 
bivalirudin in APS
Argatroban is routinely monitored by the aPTT.106 However, the 
aPTT could give unreliable results due to LA- induced effects, as 
well as during the acute phase (Table 4).28,29 In such situations, 
the dTT, which has shown comparable results using different 
analyzers, should be considered for the measurement of blood 
concentrations of the direct thrombin inhibitors argatroban107,108 
and bivalirudin.108 A therapeutic range for either remains to be 
established. ECT or ecarin chromogenic assays have been consid-
ered as alternatives, although the ECT has been demonstrated to 
have a slightly sigmoid response curve to concentration with ar-
gatroban109 and is falsely elevated by prothrombin deficiency,106 
present in APS patients with LA- hypoprothrombinemia.50 The 
ECA, although unaffected by the presence of factor deficiencies 
(due to the addition of prothrombin) or LA, has been shown to 
have a low sensitivity to argatroban.108 In critically ill patients, it 
has been suggested that TT and rotational thromboelastography 
(ROTEM) parameters may provide better correlation to argatroban 
and lepirudin (unavailable since 2012) plasma concentrations than 
APTT.110 Drug- calibrated chromogenic anti- II assays are suitable 
to monitor argatroban and bivalrudin,33 and in APS patients, would 
not be affected by any LA effects.
8.5  |  Danaparoid sodium and anticoagulation 
monitoring in APS
Danaparoid sodium is a heparinoid that catalyzes the antithrombin 
inhibition of factor Xa (Table  4). It has a long half- life of approxi-
mately 25 hours, which is a disadvantage for patients requiring ur-
gent surgery or invasive procedures.45 It has low cross- reactivity in 
vitro with sera containing HIT (heparin- platelet factor 4) antibod-
ies and is suggested as an option for HIT.77 In APS, a case report 
describes thrombosis of a cardiopulmonary bypass circuit in an 
APS patient with acute HIT, despite therapeutic danaparoid.111 
Danaparoid was reported to be effective for improving the live birth 
rate and safe for patients with obstetric APS.112 Monitoring is with 
a danaparoid calibrated anti- Xa assay.33 Danaparoid has also been 
assigned to category B by the FDA.
9  |  CONCLUSIONS
Anticoagulation monitoring in APS patients can be challenging be-
cause of LA- induced effects on phospholipid- dependent coagula-
tion tests; therefore, strategies are required to achieve effective 
anticoagulant monitoring in thrombotic APS patients. For VKA 
monitoring, the PT- INR, using an LA- insensitive thromboplastin, 
instrument- specific ISI, and local INR calibration enables representa-
tive monitoring in the majority of patients. Until further evidence is 
available, the results of POC INR testing in APS patients should be 
interpreted with caution. Although a therapeutic range is not estab-
lished for CFX use in APS patients on VKAs, this assay could assist 
in monitoring APS patients who have a prolonged PT prior to com-
mencement of VKA or experience recurrent VTE while at apparently 
therapeutic VKA anticoagulation intensity.
In APS patients, the aPTT could give unreliable results due to 
LA- induced effects, as well as those of raised CRP or factor VIII lev-
els. Given that the aPTT may not be representative of anticoagulant 
intensity in APS patients due to LA- induced and other effects, and 
the potential for patient safety issues as a result, the anti- Xa assay 
rather than the aPTT is more appropriate to monitor UFH in APS pa-
tients. The aPTT may also be unreliable to monitor argatroban and 
bivalirudin in APS patients and alternative methods are required.
The usual considerations for dosing and methods of anticoagu-
lant monitoring, when required, can be applied to APS patients on 
therapeutic doses of DOACs and LMWH. However, optimal dosing 
and target therapeutic ranges are not established for LMWH use 
in thrombotic APS, including in patients who are anticoagulant- 
refractory or pregnant. Therapeutic dosing of fondaparinux and 
danaparoid are as for non- APS patients and routine anticoagu-
lant monitoring is not generally required. TG assays remain lim-
ited to specialized laboratories and have not been standardized 
and validated for the assessment of anticoagulation intensity. 
Anticoagulant dosing and monitoring in APS patients would be 
optimized by systematic clinical and laboratory investigation to 
establish the utility of and to validate current and other potential 
approaches.
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